Energy balance modulation impacts epigenetic reprogramming, ERa and ERb expression, and mammary tumor development in MMTV-neu transgenic mice

Cancer Research

Volumn 77, Issue 9, 2017, Pages 2500-2511

  Rossi, Emily L ^a,b   Dunlap, Sarah M ^c   Bowers, Laura W ^a,b   Khatib, Subreen A ^a   Doerstling, Steven S ^a   Smith, Laura A ^a   Ford, Nikki A ^c   Holley, Darcy ^b,d   Brown, Powel H ^e   Estecio, Marcos R ^f   Kusewitt, Donna F ^f   DeGraffenried, Linda A ^c   Bultman, Scott J ^b,d   Hursting, Stephen D ^a,b  

^a University of North Carolina at Chapel Hill   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c University of Texas at Austin   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; DNA; DNA METHYLTRANSFERASE 1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; INSULIN; LEPTIN; SOMATOMEDIN C; TRANSCRIPTION FACTOR CTCF; ERBB2 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT MAINTENANCE; CALORIC RESTRICTION; CANCER INHIBITION; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; CPG ISLAND; DIET INDUCED OBESITY; DNA FLANKING REGION; DNA METHYLATION; ENERGY BALANCE; EPIGENETICS; FEMALE; FOLLOW UP; GENETIC TRANSCRIPTION; HORMONE BLOOD LEVEL; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; MOUSE; MOUSE MAMMARY TUMOR VIRUS; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK REDUCTION; TRANSCRIPTION INITIATION; TRANSGENIC MOUSE; WEIGHT REDUCTION; ANIMAL; BREAST TUMOR; CARCINOGENESIS; COMPLICATION; ENERGY METABOLISM; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; HUMAN; MAMMARY NEOPLASMS, ANIMAL; OBESITY; PATHOPHYSIOLOGY; RISK FACTOR;

ANIMALS; BREAST NEOPLASMS; CALORIC RESTRICTION; CARCINOGENESIS; DNA METHYLATION; ENERGY METABOLISM; EPIGENESIS, GENETIC; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, TRANSGENIC; OBESITY; RECEPTOR, ERBB-2; RISK FACTORS;

EID: 85018369291     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-16-2795     Document Type: Article

References (55)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7-30.
2. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer; 2013.
3. Jemal A, Bray F, Center MM, Giacinti L, Claudio PP, Lopez M, et al. Epigenetic information and estrogen receptor alpha expression in breast cancer. Oncologist 2006;11:1-8.
4. Skliris GP, Munot K, Bell SM, Carder PJ, Lane S, Horgan K, et al. Reduced expression of oestrogen receptor beta in invasive breast cancer and its reexpression using DNA methyl transferase inhibitors in a cell line model. J Pathol 2003;201:213-20.
5. Honma N, Horii R, Iwase T, Saji S, Younes M, Takubo K, et al. Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy. J Clin Oncol 2008; 26:3727-34.
6. Iwase H, Zhang Z, Omoto Y, Sugiura H, Yamashita H, Toyama T, et al. Clinical significance of the expression of estrogen receptors alpha and beta for endocrine therapy of breast cancer. Cancer Chemother Pharmacol 2003;52 Suppl 1:S34-S38.
7. Morimoto LM, White E, Chen Z, Chlebowski RT, Hays J, Kuller L, et al. Obesity, body size, and risk of postmenopausal breast cancer: the Women's Health Initiative (United States). Cancer Causes Control 2002;13:741-51.
8. Vona-Davis L, Rose DP. Type 2 diabetes and obesity metabolic interactions: common factors for breast cancer risk and novel approaches to prevention and therapy. Curr Diabetes Rev 2012;8:116-30.
9. Alokail MS, Al-Daghri NM, Al-Attas OS, Hussain T. Combined effects of obesity and type 2 diabetes contribute to increased breast cancer risk in premenopausal women. Cardiovasc Diabetol 2009;8:33.
10. Healy LA, Ryan AM, Carroll P, Ennis D, Crowley V, Boyle T, et al. Metabolic syndrome, central obesity and insulin resistance are associated with adverse pathological features in postmenopausal breast cancer. Clin Oncol 2010;22:281-8.
11. Litton JK, Gonzalez-Angulo AM, Warneke CL, Buzdar AU, Kau SW, Bondy M, et al. Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer. J Clin Oncol 2008;26:4072-7.
12. Hursting SD, Smith SM, Lashinger LM, Harvey AE, Perkins SN. Calories and carcinogenesis: Lessons learned from 30 years of calorie restriction research. Carcinogenesis 2009;31:83-9.
13. Colman RJ, Anderson RM, Johnson SC, Kastman EK, Kosmatka KJ, Beasley TM, et al. Caloric restriction delays disease onset and mortality in rhesus monkeys. Science 2009;325:201-4.
14. Fabian CJ, Kimler BF, Donnelly JE, Sullivan DK, Klemp JR, Petroff BK, et al. Favorable modulation of benign breast tissue and serum risk biomarkers is associated with >10% weight loss in postmenopausal women. Breast Cancer Res Treat 2013;142:119-32.
15. Harvie M, Wright C, Pegington M, McMullan D,Mitchell E, Martin B, et al. The effect of intermittent energy and carbohydrate restriction v. daily energy restriction on weight loss and metabolic disease risk markers in overweight women. Br J Nutr 2013;110:1534-47.
16. Donohoe DR, Bultman SJ. Metaboloepigenetics: Interrelationships between energy metabolism and epigenetic control of gene expression. J Cell Physiol 2012;227:3169-77.
17. Portela A, Esteller M. Epigenetic modifications and human disease. Nat Biotechnol 2010;28:1057-68.
18. Waterland RA, Michels KB. Epigenetic epidemiology of the developmental origins hypothesis. Annu Rev Nutr 2007;27:363-88.
19. Sharma NK, Varma V, Ma L, Hasstedt SJ, Das SK. Obesity associated modulation of miRNA and co-regulated target transcripts in human adipose tissue of non-diabetic subjects. Microrna 2015;4:194-204.
20. Mutze K, Langer R, Schumacher F, Becker K, Ott K, Novotny A, et al. DNA methyltransferase 1 as a predictive biomarker and potential therapeutic target for chemotherapy in gastric cancer. Eur J Cancer 2011;47:1817-25.
21. Yu D-H, Ware C, Waterland RA, Zhang J, Chen M-H, Gadkari M, et al. Developmentally programmed 30 CpG islandmethylation confers tissue-and cell-type-specific transcriptional activation. Mol Cell Biol 2013;33:1845-58.
22. Jones PA. The DNA methylation paradox. Trends Genet 1999;15:34-7.
23. Lai AY, Fatemi M, Dhasarathy A, Malone C, Sobol SE, Geigerman C, et al. DNA methylation prevents CTCF-mediated silencing of the oncogene BCL6 in B cell lymphomas. J Exp Med 2010;207:1939-50.
24. Ong C-T, Corces VG. CTCF: an architectural protein bridging genome topology and function. Nat Rev Genet 2014;15:234-46.
25. Wang H, Maurano MT, Qu H, Varley KE, Gertz J, Pauli F, et al. Widespread plasticity in CTCF occupancy linked to DNA methylation. Genome Res 2012;22:1680-8.
26. Rowse GJ, Tempero RM, VanLith ML, Hollingsworth MA, Gendler SJ. Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model. Cancer Res 1998;58:315-21.
27. Thomas DG, Breslow N, Gart JJ. Trend and homogeneity analysis of proportions and life table data. Comput and Biomed Res 1977;10:373-81.
28. Browne RW, Kantarci A, LaMonte MJ, Andrews CA, Hovey KM, Falkner KL, et al. Performance of multiplex cytokine assays in serum and saliva among community-dwelling postmenopausal women. PLoS One 2013;8:e59498.
29. Rossi EL, de Angel RE, Bowers LW, Khatib SA, Smith LA, Van Burren E, et al. Obesity-associated alterations in inflammation, epigenetics, andmammary tumor growth persist in formerly obese mice. Cancer Prev Res 2016; 9:339-48.
30. Yates A, Akanni W, Amode MR, Barrell D, Billis K, Carvalho-Silva D, et al. Ensembl 2016. Nucleic Acids Res 2016;44:D710-6.
31. Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, Salzberg SL. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol 2013;14:1-13.
32. Pruitt KD, Tatusova T, Brown GR, Maglott DR. NCBI Reference Sequences (RefSeq): current status, new features and genome annotation policy. Nucleic Acids Res 2012;40:130-5.
33. Zhang Q, Wang HY, Woetmann A, Raghunath PN, Odum N, Wasik MA. STAT3 induces transcription of the DNA methyltransferase 1 gene (DNMT1) in malignant T lymphocytes. Blood 2006;108:1058-64.
34. Zhang BG, Hu L, Zang MD, Wang HX, Zhao W, Li JF, et al. Helicobacter pylori CagA induces tumor suppressor gene hypermethylation by upregulated DNMT1 via AKT-NFkB pathway in gastric cancer development. Oncotarget 2016;7:9788-800.
35. Kimura H, Nakamura T, Ogawa T, Tanaka S, Shiota K. Transcription of mouse DNA methyltransferase 1 (Dnmt1) is regulated by both E2F-Rb-HDAC-dependent and-independent pathways. Nucleic Acids Res 2003; 31:3101-13.
36. Nogueira LM, Dunlap SM, Ford NA, Hursting SD. Calorie restriction and rapamycin inhibit MMTV-Wnt-1 mammary tumor growth in a mouse model of postmenopausal obesity. Endocr Relat Cancer 2012;19:57-68.
37. Olivo-Marston SE, Hursting SD, Perkins SN, Schetter A, Khan M, Croce C, et al. Effects of calorie restriction and diet-induced obesity on murine colon carcinogenesis, growth and inflammatory factors, and MicroRNA expression. PLoS One 2014;9:e94765.
38. Madeira M, Mattar A, Logullo AF, Soares FA, Gebrim LH. Estrogen receptor alpha/beta ratio and estrogen receptor beta as predictors of endocrine therapy responsiveness-a randomized neoadjuvant trial comparison between anastrozole and tamoxifen for the treatment of postmenopausal breast cancer. BMC Cancer 2013;13:425.
39. Nadal-Serrano M, Sastre-Serra J, Pons DG, Miró AM, Oliver J, Roca P. The ERalpha/ERbeta ratio determines oxidative stress in breast cancer cell lines in response to 17Beta-estradiol. J Cell Biochem 2012;113:3178-85.
40. Barres R, Kirchner H, RasmussenM, Yan J, Kantor F, Krook A, et al. Weight loss after gastric bypass surgery in human obesity remodels promoter methylation. Cell Rep 2013;3:1020-7.
41. Yan H, Tang G, Wang H, Hao L, He T, Sun X, et al. DNA methylation reactivates GAD1 expression in cancer by preventing CTCF-mediated polycomb repressive complex 2 recruitment. Oncogene 2015;35:1-14.
42. Victoria-Acosta G, Vazquez-Santillan K, Jimenez-Hernandez L, Muñoz-Galindo L, Maldonado V, Martinez-Ruiz GU, et al. Epigenetic silencing of the XAF1 gene is mediated by the loss of CTCF binding. Sci Rep 2015; 5:14838.
43. Hark AT, Schoenherr CJ, Katz DJ, Ingram RS, Levorse JM, Tilghman SM. CTCF mediates methylation-sensitive enhancer blocking activity at the H19/Igf2 locus. Nature 2000;405:486-90.
44. Filippova GN, Fagerlie S, Klenova EM, Myers C, Dehner Y, Goodwin G, et al. An exceptionally conserved transcriptional repressor, CTCF, employs different combinations of zinc fingers to bind diverged promoter sequences of avian and mammalian c-myc oncogenes. Mol Cell Biol 1996;16:2802-13.
45. Mizuno NK, Rogozina OP, Seppanen CM, Liao DJ, Cleary MP, Grossmann ME. Combination of Intermittent calorie restriction and eicosapentaenoic acid for inhibition of mammary tumors. Cancer Prev Res 2013;6:540-7.
46. Engelman RW, Day NK, Good RA. Calorie intake during mammary development influences cancer risk: Lasting inhibition of C3H/HeOu mammary tumorigenesis by peripubertal calorie restriction. Cancer Res 1994;54:5724-30.
47. Nogueira LM, Lavigne JA, Chandramouli GV, Lui H, Barrett JC, Hursting SD. Dose-dependent effects of calorie restriction on gene expression, metabolism, and tumor progression are partially mediated by insulin-like growth factor-1. Cancer Med 2012;1:275-88.
48. Cleary MP, Grande JP, Juneja SC, Maihle NJ. Diet-induced obesity and mammary tumor development in MMTV-neu female mice. Nutr Cancer 2004;50:174-80.
49. Chen CT, Du Y, Yamaguchi H, Hsu JM, Kuo HP, Hortobagyi GN, et al. Targeting the IKKbeta/mTOR/VEGF signaling pathway as a potential therapeutic strategy for obesity-related breast cancer. Mol Cancer Ther 2012;11:2212-21.
50. The Endogenous Hormones and Breast Cancer Collaborative Group. Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet Oncol 2010;11:530-42.
51. Horne HN, Sherman ME, Pfeiffer RM, Figueroa JD, Khodr ZG, Falk RT, et al. Circulating insulin-like growth factor-1, insulin-like growth factor binding protein-3 and terminal duct lobular unit involution of the breast: a crosssectional study of women with benign breast disease. Breast Cancer Res 2016;18:24.
52. Chen MF, Lin PY, Wu CF, Chen WC, Wu CT. IL-6 expression regulates tumorigenicity and correlates with prognosis in bladder cancer. PLoS One 2013;8:e61901.
53. Murphy TM, O'Donovan A, Mullins N, O'Farrelly C, McCann A, Malone K. Anxiety is associated with higher levels of global DNA methylation and altered expression of epigenetic interleukin-6 genes. Psychiatry Genet 2015;25:71-8.
54. Roy DM, Walsh LA, Chan TA. Driver mutations of cancer epigenomes. Protein Cell 2014;5:265-96.
55. Padovani M, Lavigne JA, Chandramouli GV, Perkins SN, Barrett JC, Hursting SD, et al. Distinct effects of calorie restriction and exercise on mammary gland gene expression in C57BL/6 mice. Cancer Prev Res 2009;2:1076-87.